Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jun;6(12):e13743.
doi: 10.14814/phy2.13743.

Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome; a case report

Affiliations
Case Reports

Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome; a case report

Gitte R Hinrichs et al. Physiol Rep. 2018 Jun.

Abstract

Sodium and fluid retention is a hallmark and a therapeutic challenge of the nephrotic syndrome (NS). Studies support the "overfill" theory of NS with pathophysiological proteolytic activation of the epithelial sodium channel (ENaC) which explains the common observation of suppressed renin -angiotensin system and poor therapeutic response to ACE inhibitors. Blockade of ENaC by the diuretic amiloride would be a rational intervention compared to the traditionally used loop diuretics. We describe a 38-year-old male patient with type1 diabetes who developed severe hypertension (200/140 mmHg), progressive edema (of at least 10 L), and overt proteinuria (18.5 g/24 h), despite combined administration of five antihypertensive drugs. Addition of amiloride (5 mg/day) to treatment resulted in resolution of edema, weight loss of 7 kg, reduction in blood pressure (150/100-125/81 mmHg), increased 24 h urinary sodium excretion (127-165 mmol/day), decreased eGFR (41-29 mL/min), and increased plasma potassium concentration (4.6-7.8 mmol/L). Blocking of ENaC mobilizes nephrotic edema and lowers blood pressure in NS. However, acute kidney injury and dangerous hyperkalemia is a potential risk if amiloride is added to multiple other antihypertensive medications as ACEi and spironolactone. The findings support that ENaC is active in NS and is a relevant target in adult NS patients.

Keywords: ENaC; plasmin; protease; proteinuria.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A): Overview of the increasing doses and numbers of the antihypertensive and diuretic drugs in a timeline. (B) Blood pressure decreased slowly and insufficiently despite several antihypertensive drugs, but at administration of amiloride (week 15), blood pressure, and weight declined promptly and effectively. (C) Combined treatment directed at aldosterone/ENaC resulted in severe hyperkalemia and a decline in kidney function. (D) Addition of amiloride increased urinary sodium excretion. Furthermore, proteinuria decreased.

Comment in

Similar articles

Cited by

References

    1. Andersen, H. , Hansen P. B., Bistrup C., Nielsen F., Henriksen J. E., and Jensen B. L.. 2016. Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy. J. Hypertens. 34:1621–1629. - PubMed
    1. Bobrie, G. , Frank M., Azizi M., Peyrard S., Boutouyrie P., Chatellier G., et al. 2012. Sequential nephron blockade versus sequential renin‐angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J. Hypertens. 30:1656–1664. - PubMed
    1. Bohnert, B. N. , Menacher M., Janessa A., Worn M., Schork A., Daiminger S., et al. 2017. Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome. Kidney Int. 000:00. - PubMed
    1. Brown, E. A. , Markandu N. D., Roulston J. E., Jones B. E., Squires M., and MacGregor G. A.. 1982a. Is the renin‐angiotensin‐aldosterone system involved in the sodium retention in the nephrotic syndrome? Nephron 32:102–107. - PubMed
    1. Brown, E. A. , Markandu N. D., Sagnella G. A., Squires M., Jones B. E., and MacGregor G. A.. 1982b. Evidence that some mechanism other than the renin system causes sodium retention in nephrotic syndrome. Lancet (London, England) 2: 1237–1240. - PubMed

Publication types

MeSH terms